EP2961765A4 - Modulateurs à petites molécules de pcsk9 et leurs procédés d'utilisation - Google Patents

Modulateurs à petites molécules de pcsk9 et leurs procédés d'utilisation

Info

Publication number
EP2961765A4
EP2961765A4 EP14765405.7A EP14765405A EP2961765A4 EP 2961765 A4 EP2961765 A4 EP 2961765A4 EP 14765405 A EP14765405 A EP 14765405A EP 2961765 A4 EP2961765 A4 EP 2961765A4
Authority
EP
European Patent Office
Prior art keywords
pcsk9
methods
small molecule
molecule modulators
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14765405.7A
Other languages
German (de)
English (en)
Other versions
EP2961765A1 (fr
Inventor
Daniel Guay
Sheldon Crane
Nicolas Lachance
Jean-François Chiasson
Vouy Linh Truong
Patrick Lacombe
Kathryn Skorey
Nabil G Seidah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaerata LP
Original Assignee
Adaerata LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaerata LP filed Critical Adaerata LP
Publication of EP2961765A1 publication Critical patent/EP2961765A1/fr
Publication of EP2961765A4 publication Critical patent/EP2961765A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP14765405.7A 2013-03-15 2014-03-14 Modulateurs à petites molécules de pcsk9 et leurs procédés d'utilisation Withdrawn EP2961765A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792249P 2013-03-15 2013-03-15
PCT/CA2014/050255 WO2014139008A1 (fr) 2013-03-15 2014-03-14 Modulateurs à petites molécules de pcsk9 et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP2961765A1 EP2961765A1 (fr) 2016-01-06
EP2961765A4 true EP2961765A4 (fr) 2016-11-09

Family

ID=51535727

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14765405.7A Withdrawn EP2961765A4 (fr) 2013-03-15 2014-03-14 Modulateurs à petites molécules de pcsk9 et leurs procédés d'utilisation

Country Status (10)

Country Link
US (1) US20160031935A1 (fr)
EP (1) EP2961765A4 (fr)
JP (1) JP2016511274A (fr)
KR (1) KR20150132362A (fr)
CN (1) CN105431447A (fr)
AU (1) AU2014231330A1 (fr)
BR (1) BR112015023761A2 (fr)
CA (1) CA2905237A1 (fr)
HK (1) HK1222864A1 (fr)
WO (1) WO2014139008A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
US10034892B2 (en) 2014-08-21 2018-07-31 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity
WO2016040305A1 (fr) * 2014-09-08 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Inhibiteurs de pcsk9 et leurs procédés d'utilisation
KR20170123345A (ko) * 2015-03-20 2017-11-07 오르후스 우니베르시테트 지질단백질 대사 장애의 치료를 위한 pcsk9의 억제제
CA3026074A1 (fr) 2016-06-01 2017-12-07 M3 Biotechnology, Inc. Composes de l'amide n-hexanoique-l-tyrosine-l-isoleucine-(6)-aminohexanoique et leur utilisation pour traiter les maladies neurodegeneratives
MX2018016057A (es) 2016-06-24 2019-05-06 Hoffmann La Roche Composiciones y metodos para tratar enfermedades cardiovasculares.
GB2567210B (en) 2017-10-06 2020-01-15 Rolls Royce Plc A bladed disk
CN109096247A (zh) * 2018-08-15 2018-12-28 上海罕道医药科技有限公司 一种3h双吖丙啶基双取代吡啶衍生物的制备方法
WO2020150473A2 (fr) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Inhibiteurs de pcsk9 et leurs procédés d'utilisation
LV15544A (lv) * 2019-07-01 2021-01-20 Latvijas Organiskās Sintēzes Institūts Jauni borskābi saturoši peptidomimētiķi kā malārijas serīna proteāzes inhibitori

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866684A (en) * 1996-11-18 1999-02-02 Hoffmann-La Roche Inc. Peptidyl inhibitors of viral proteases
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
WO2013123456A1 (fr) * 2012-02-16 2013-08-22 Rqx Pharmaceuticals, Inc. Antibiotiques à peptide linéaire

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180586B1 (en) * 1996-09-24 2001-01-30 The Procter & Gamble Company Liquid laundry detergent compositions containing proteolytic enzyme and protease inhibitors
JP2005531540A (ja) * 2002-04-30 2005-10-20 トラスティーズ・オブ・タフツ・カレッジ セリンプロテアーゼ阻害剤のスマートプロドラッグ
EP2137218A2 (fr) * 2007-04-13 2009-12-30 Novartis Ag Molécules et procédés de modulation de proprotéine convertase subtilisine/kexine de type 9 (pcsk9)
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
SG183843A1 (en) * 2010-03-01 2012-10-30 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866684A (en) * 1996-11-18 1999-02-02 Hoffmann-La Roche Inc. Peptidyl inhibitors of viral proteases
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
WO2013123456A1 (fr) * 2012-02-16 2013-08-22 Rqx Pharmaceuticals, Inc. Antibiotiques à peptide linéaire

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AROSIO M ET AL: "LDL PHYSICAL PROPERTIES, LIPOPROTEIN AND LP(A) LEVELS IN ACROMEGALIC PATIENTS. EFFECTS OF OCTREOTIDE THERAPY", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, vol. 151, no. 2, 1 August 2000 (2000-08-01), pages 551 - 557, XP000918773, ISSN: 0021-9150, DOI: 10.1016/S0021-9150(99)00426-8 *
DUNSDON R M ET AL: "Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 10, no. 14, 17 July 2000 (2000-07-17), pages 1577 - 1579, XP004209707, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(00)00284-5 *
MORRIS ET AL: "In Vitro and Ex Vivo Inhibition of Hepatitis A Virus 3C Proteinase by a Peptidyl Monofluromethyl Ketone", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 5, no. 5, 1 May 1997 (1997-05-01), pages 797 - 807, XP002339902, ISSN: 0968-0896, DOI: 10.1016/S0968-0896(97)88649-X *
See also references of WO2014139008A1 *

Also Published As

Publication number Publication date
CA2905237A1 (fr) 2014-09-18
WO2014139008A1 (fr) 2014-09-18
CN105431447A (zh) 2016-03-23
AU2014231330A1 (en) 2015-10-01
JP2016511274A (ja) 2016-04-14
HK1222864A1 (zh) 2017-07-14
BR112015023761A2 (pt) 2017-07-18
US20160031935A1 (en) 2016-02-04
KR20150132362A (ko) 2015-11-25
EP2961765A1 (fr) 2016-01-06

Similar Documents

Publication Publication Date Title
HK1248596A1 (zh) 新型sez6調節劑以及應用方法
IL280155A (en) Anti- SIGLEC-8 antibodies and methods of using them
IL290547A (en) Antibodies and methods of use
HK1223913A1 (zh) 經取代的苯甲酰胺及其使用方法
IL244495A0 (en) Anti-alpha-synuclein antibodies and methods of use
HK1222864A1 (zh) 的小分子調節劑和其使用方法
HK1217720A1 (zh) 選擇性遞送分子及使用方法
HK1225612A1 (zh) 抗ly6e抗體及使用方法
HK1224307A1 (zh) 原毒素- 變體及其使用方法
EP3027182A4 (fr) Nouveau matériau de cuivre-cystéamine et procédés d'utilisation
EP2895474A4 (fr) Modulateurs de smoothened et leurs procédés d'utilisation
AU2013902334A0 (en) Biological molecules and methods of use
AU2013902101A0 (en) Biosorbent and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161011

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 5/08 20060101ALI20161005BHEP

Ipc: C07K 5/083 20060101AFI20161005BHEP

Ipc: C07K 5/027 20060101ALI20161005BHEP

Ipc: A61P 3/06 20060101ALI20161005BHEP

Ipc: A61K 38/06 20060101ALI20161005BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170509